Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology
Roche has unveiled its breakthrough sequencing by expansion (SBX) technology, establishing a new category of next-generation sequencing (NGS). The innovative technology combines sophisticated biochemistry with a high-throughput sensor module to determine DNA sequences using expanded synthetic molecules called Xpandomers.
The SBX technology creates Xpandomers that are fifty times longer than the original molecule and provide clear signals with minimal background noise. This enables highly accurate single-molecule nanopore sequencing using a CMOS-based sensor module with parallel processing capabilities. The technology can reduce genome sequencing time from days to hours, offering unprecedented speed, efficiency, and flexibility.
The technology aims to enhance genomic research and decode complex diseases like cancer, immune disorders, and neurodegenerative conditions. Its ultra-rapid, high-throughput, flexible, and scalable nature makes it suitable for various applications, with potential future adoption in clinical lab settings.
Roche ha svelato la sua innovativa tecnologia di sequenziamento per espansione (SBX), stabilendo una nuova categoria di sequenziamento di nuova generazione (NGS). Questa tecnologia all'avanguardia combina una sofisticata biochimica con un modulo sensore ad alta capacità per determinare le sequenze di DNA utilizzando molecole sintetiche espanse chiamate Xpandomers.
La tecnologia SBX crea Xpandomers che sono cinquanta volte più lunghi della molecola originale e forniscono segnali chiari con un rumore di fondo minimo. Ciò consente un sequenziamento nanopore a singola molecola altamente accurato utilizzando un modulo sensore basato su CMOS con capacità di elaborazione parallela. La tecnologia può ridurre il tempo di sequenziamento del genoma da giorni a ore, offrendo una velocità, un'efficienza e una flessibilità senza precedenti.
Questa tecnologia mira a migliorare la ricerca genomica e a decifrare malattie complesse come il cancro, i disturbi immunitari e le condizioni neurodegenerative. La sua natura ultra-rapida, ad alta capacità, flessibile e scalabile la rende adatta a varie applicazioni, con potenziale adozione futura in contesti di laboratorio clinico.
Roche ha presentado su innovadora tecnología de secuenciación por expansión (SBX), estableciendo una nueva categoría de secuenciación de nueva generación (NGS). Esta tecnología innovadora combina una bioquímica sofisticada con un módulo de sensor de alto rendimiento para determinar secuencias de ADN utilizando moléculas sintéticas ampliadas llamadas Xpandomers.
La tecnología SBX crea Xpandomers que son cincuenta veces más largos que la molécula original y proporcionan señales claras con un ruido de fondo mínimo. Esto permite una secuenciación nanopore de molécula única altamente precisa utilizando un módulo de sensor basado en CMOS con capacidades de procesamiento paralelo. La tecnología puede reducir el tiempo de secuenciación del genoma de días a horas, ofreciendo una velocidad, eficiencia y flexibilidad sin precedentes.
La tecnología tiene como objetivo mejorar la investigación genómica y descifrar enfermedades complejas como el cáncer, trastornos inmunitarios y condiciones neurodegenerativas. Su naturaleza ultra-rápida, de alto rendimiento, flexible y escalable la hace adecuada para diversas aplicaciones, con una posible adopción futura en entornos de laboratorio clínico.
로슈(Roche)는 혁신적인 확장에 의한 시퀀싱 기술(SBX)을 공개하며 차세대 시퀀싱(NGS)의 새로운 범주를 설정했습니다. 이 혁신적인 기술은 정교한 생화학과 고처리량 센서 모듈을 결합하여 Xpandomer라는 확장된 합성 분자를 사용하여 DNA 서열을 결정합니다.
SBX 기술은 원래 분자보다 50배 긴 Xpandomer를 생성하며, 최소한의 배경 소음으로 명확한 신호를 제공합니다. 이는 CMOS 기반 센서 모듈을 사용한 단일 분자 나노포어 시퀀싱을 통해 높은 정확도를 가능하게 합니다. 이 기술은 유전체 시퀀싱 시간을 며칠에서 몇 시간으로 단축할 수 있어 전례 없는 속도, 효율성 및 유연성을 제공합니다.
이 기술은 유전체 연구를 개선하고 암, 면역 질환 및 신경퇴행성 질환과 같은 복잡한 질병을 해독하는 것을 목표로 합니다. 초고속, 고처리량, 유연하고 확장 가능한 특성 덕분에 다양한 응용 분야에 적합하며, 향후 임상 실험실 환경에서의 채택 가능성도 있습니다.
Roche a dévoilé sa technologie révolutionnaire de séquençage par expansion (SBX), établissant une nouvelle catégorie de séquençage de nouvelle génération (NGS). Cette technologie innovante combine une biochimie sophistiquée avec un module de capteur à haut débit pour déterminer les séquences d'ADN à l'aide de molécules synthétiques étendues appelées Xpandomers.
La technologie SBX crée des Xpandomers qui sont cinquante fois plus longs que la molécule d'origine et fournissent des signaux clairs avec un bruit de fond minimal. Cela permet un séquençage nanopore de molécules uniques hautement précis à l'aide d'un module de capteur basé sur des CMOS avec des capacités de traitement parallèle. La technologie peut réduire le temps de séquençage du génome de plusieurs jours à quelques heures, offrant une vitesse, une efficacité et une flexibilité sans précédent.
Cette technologie vise à améliorer la recherche génomique et à déchiffrer des maladies complexes telles que le cancer, les troubles immunitaires et les maladies neurodégénératives. Sa nature ultra-rapide, à haut débit, flexible et évolutive la rend adaptée à diverses applications, avec un potentiel d'adoption future dans des environnements de laboratoire clinique.
Roche hat seine bahnbrechende Sequenzierung durch Expansion (SBX)-Technologie vorgestellt und damit eine neue Kategorie der Next-Generation-Sequencing (NGS) etabliert. Diese innovative Technologie kombiniert anspruchsvolle Biochemie mit einem Hochdurchsatz-Sensormodul, um DNA-Sequenzen mithilfe erweiterter synthetischer Moleküle, den sogenannten Xpandomeren, zu bestimmen.
Die SBX-Technologie erzeugt Xpandomere, die fünfzigmal länger sind als das ursprüngliche Molekül und klare Signale mit minimalem Hintergrundrauschen liefern. Dies ermöglicht eine hochgenaue Einzelmolekül-Nanopore-Sequenzierung mit einem auf CMOS basierenden Sensormodul mit parallelen Verarbeitungskapazitäten. Die Technologie kann die Genomsequenzierungszeit von Tagen auf Stunden reduzieren und bietet beispiellose Geschwindigkeit, Effizienz und Flexibilität.
Die Technologie zielt darauf ab, die genomische Forschung zu verbessern und komplexe Krankheiten wie Krebs, Immunerkrankungen und neurodegenerative Erkrankungen zu entschlüsseln. Ihre ultra-schnelle, hochdurchsatzfähige, flexible und skalierbare Natur macht sie für verschiedene Anwendungen geeignet, mit potenzieller zukünftiger Anwendung in klinischen Laborumgebungen.
- Introduction of revolutionary SBX technology that reduces genome sequencing time from days to hours
- Technology offers superior signal-to-noise ratio through Xpandomers, enabling more accurate sequencing
- Flexible system capable of operating across various throughput scales
- Potential for broad applications in research and clinical settings
- None.
- Roche's innovative sequencing by expansion (SBX) technology represents a leap forward in next-generation sequencing (NGS), which is playing a vital role in decoding complex diseases like cancer, immune disorders and neurodegenerative conditions
- Combined with an innovative, high throughput sensor module, SBX uses expanded synthetic molecules to determine the DNA sequence of a target molecule, creating an ultra-rapid, scalable and flexible technology
- Reducing the time from sample to genome from days to hours, this novel approach could significantly speed up genomic research, as well as translational and clinical applications in the years to come
Basel, 20 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) unveiled today its proprietary, breakthrough sequencing by expansion (SBX) technology, establishing a new category of next-generation sequencing. SBX chemistry, combined with an innovative sensor module, offers ultra-rapid, high-throughput sequencing that is both flexible and scalable for a broad range of applications.
Next-generation sequencing provides detailed insights into genetics, genomics and cell biology. It has already improved our understanding of gene functions and interaction, and is critical to our ability to decode complex diseases such cancer, immune disorders, and neurodegenerative conditions, where hundreds or even thousands of genes impact disease progression.
“The science behind SBX technology represents a significant breakthrough that addresses the limitations of existing sequencing solutions,” states Matt Sause, CEO of Roche Diagnostics. “By integrating and enhancing the two technologies, Roche's SBX has created a differentiated approach, offering unparalleled speed, efficiency and flexibility. The speed and accuracy of SBX has the potential to revolutionise the use of sequencing in research and healthcare.”
SBX is a novel sequencing approach which uses a sophisticated biochemical process to encode the sequence of a target nucleic acid molecule (DNA or RNA) into a measurable surrogate polymer called an Xpandomer. Xpandomers, which are fifty times longer than the original molecule, encode the sequence information into high signal-to-noise reporters, meaning they provide clear signals with minimal background noise. This enables highly accurate single-molecule nanopore sequencing using a Complementary Metal Oxide Semiconductor (CMOS)-based sensor module with parallel processing capabilities, offering speed and flexibility beyond that of other sequencing technologies.
“Solving the signal-to-noise challenge is a key efficiency driver for the technology. With this capability we can flexibly operate across a range of throughput scales using the same sequencing system, which provides a significant advantage to users,” said Mark Kokoris, Head of Roche's SBX Technology.
The ability of SBX technology to provide ultra-rapid, high-throughput, flexible and scalable sequencing lends itself to a broad range of projects and applications. This technology will enable researchers to make significant discoveries that enhance our understanding of diseases and their treatment, with the potential to drive greater adoption in the clinical lab setting in the future.
About Sequencing by Expansion (SBX) technology
Roche's groundbreaking next-generation sequencing technology is designed to overcome the limitations of traditional sequencing methods. As well as high accuracy, it also offers an unparalleled combination of flexibility and speed, making it a versatile tool for a wide range of genomic applications.
One of the key benefits of SBX technology is its scalability. The chemistry is coupled with an advanced, high-throughput CMOS sensor module that enables ultra-rapid, real-time base calls and analysis. This module is designed to process numerous samples simultaneously, creating a highly scalable and flexible architecture for cost-efficient sequencing across different project sizes, from small-scale studies to large projects involving thousands of samples.
This versatility makes SBX technology suitable for a variety of applications, including whole genome sequencing, whole exome sequencing, and RNA sequencing. As a result, it holds promise not only for research laboratories but also eventually for clinical settings where detailed genomic insights are crucial. With SBX technology, researchers can meet new and evolving research demands efficiently, paving the way for significant advances in our understanding of genetics and disease, ultimately contributing to better healthcare outcomes.
SBX chemistry was invented by Mark Kokoris and Robert McRuer who co-founded Stratos Genomics. Stratos Genomics was acquired by Roche in 2020. To find out more about Roche’s novel SBX technology, click here.
About Roche’s Sequencing Portfolio
Roche has been committed to providing next-generation sequencing library prep solutions and application support for sequencing for several years. Today, next-generation sequencing solutions from Roche play an important role in the sequencing ecosystem. Our KAPA sample preparation products offer high-performance DNA, RNA library prep and target enrichment solutions for a variety of applications. Additionally, we offer the AVENIO Edge system that provides a true walk-away automated solution for many of our KAPA kits. This system does not require advanced programming skills and comes with ready-to-use kits and protocols. Our AVENIO assays offer robust solutions for oncology, including the recent approval of the AVENIO Tumor Tissue CGP Automated Kit, a collaboration between Roche and Foundation Medicine, two leaders in oncology.
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
| Hans Trees, PhD Phone: +41 79 407 72 58 | Sileia Urech Phone: +41 79 935 81 48 |
| Nathalie Altermatt Phone: +41 79 771 05 25 | Lorena Corfas Phone: +41 79 568 24 95 |
| Simon Goldsborough Phone: +44 797 32 72 915 | Karsten Kleine Phone: +41 79 461 86 83 |
| Nina Mählitz Phone: +41 79 327 54 74 | Kirti Pandey Phone: +49 172 6367262 |
| Yvette Petillon Phone: +41 79 961 92 50 | Dr Rebekka Schnell Phone: +41 79 205 27 03 |
Roche Investor Relations
| Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com | Dr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com |
| Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com |
Investor Relations North America
| Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com |
Attachment
FAQ
What is Roche's new SBX technology and how does it differ from traditional sequencing (RHHBY)?
How much faster is Roche's new SBX sequencing technology (RHHBY)?
What applications will Roche's SBX technology have in healthcare (RHHBY)?
What are the key advantages of Roche's SBX technology for researchers (RHHBY)?
